{"entity":{"id":"can-fite","kind":"company","name":"Can-Fite BioPharma","aka":["Can-Fite BioPharma Ltd","Can Fite Biopharma"],"tldr":"Can-Fite is an Israeli company developing adenosine A3 receptor agonists; namodenoson is in phase 3 as a second-line treatment for liver cancer in patients with poor liver function.","summary":"Can-Fite BioPharma, founded in 1994 and based in Petah Tikva, Israel, develops small molecules that act on the adenosine A3 receptor, which is overexpressed in tumour and inflamed cells. Namodenoson is in a phase 3 trial in hepatocellular carcinoma with Child-Pugh B liver function, a group with few options, and piclidenoson is tested in psoriasis. Its trials are registered on ClinicalTrials.gov under Can-Fite as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.canfite.com"},{"label":"ClinicalTrials.gov: trials led by Can-Fite BioPharma Ltd","url":"https://clinicaltrials.gov/search?lead=Can-Fite%20BioPharma%20Ltd"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q96482303"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Petah Tikva","country":"IL","companyType":"biotech","website":"https://www.canfite.com","founded":1994,"stage":"public","investors":[],"funding":[]},"route":"/companies/can-fite/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}]}}